Oxygen acquires rights to FDA fast-track heart surgery drug
This article was originally published in Scrip
Executive Summary
Oxygen Biotherapeutics will acquire assets of privately held biopharmaceutical company, Phyxius Pharma – including cardiac surgery drug levosimendan, which has FDA fast-track status.